We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold Nanoparticle-Based Test Better for Prostate Cancer Diagnosis Than PSA

By LabMedica International staff writers
Posted on 13 Apr 2015
A rapid and simple gold nanoparticle-based blood test proved better at diagnosing prostate cancer than did the commonly used PSA (prostate-specific antigen) assay.

Investigators at the University of Central Florida (Orlando, USA) based their NanoDLSay test on the ability of gold nanoparticles to bind certain proteins from the serum and to increase in size and change their light scattering properties.

When citrate ligands-capped gold nanoparticles are mixed with blood sera, a protein corona is formed on the nanoparticle surface due to the adsorption of various proteins in the blood to the nanoparticles. More...
Using a two-step gold nanoparticle-enabled dynamic light scattering assay, the investigators discovered that the amount of human immunoglobulin G (IgG) in the gold nanoparticle protein corona was increased in prostate cancer patients compared to healthy controls. Two pilot studies conducted on blood serum samples collected at Florida Hospital (USA) and obtained from the Prostate Cancer Biorespository Network revealed that the test had 90%–95% specificity and 50% sensitivity in detecting early stage prostate cancer, representing a significant improvement over the current PSA test.

The investigators postulated that the increased amount of human IgG found in the protein corona was associated with the autoantibodies produced in cancer patients as part of the immune system's defense against the tumor. Proteomic analysis of the nanoparticle protein corona revealed molecular profile differences between serum samples from cancer patients and healthy individuals. Autoantibodies and natural antibodies produced in cancer patients in response to tumorigenesis have been found and detected in the blood of many cancer types. Thus, the test may be applicable for early detection and risk assessment of a broad spectrum of cancer types.

"What is different and unique about our technique is it is a very simple process, and the material required for the test is less than one USD," said senior author Dr. Qun Huo, professor of chemistry at the University of Central Florida. "And because it is low-cost, we are hoping most people can have this test in their doctor's office. If we can catch this cancer in its early stages, the impact is going to be big."

The investigators have founded the biomedical company Nano Discovery Inc. (Orlando, FL, USA) to commercialize the NanoDLSay diagnostic test for prostate cancer.

The report was published in the March 10, 2015, online edition of the journal ACS Applied Materials & Interfaces.

Related Links:
University of Central Florida
Nano Discovery Inc.



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.